Business
Press Release May 28 2026
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA".
About this update from Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". View Attachment
View stock analysis, news, and events for Zydus Lifesciences Limited